Management of H. pylori Infection After Quadruple Therapy Failure

Second-Line Treatment Algorithm

The American Gastroenterological Association recommends levofloxacin-based triple therapy as the second-line option after bismuth quadruple therapy failure, consisting of a PPI at standard dose twice daily, amoxicillin 1000 mg twice daily, and levofloxacin 500 mg once daily for 14 days 1, 2, 3
The European Helicobacter Study Group suggests that combining bismuth with levofloxacin significantly enhances efficacy to 90-91% cure rates, making a quadruple regimen of PPI + amoxicillin + levofloxacin + bismuth for 14 days a superior alternative if bismuth is available 1, 2, 3
Do not use levofloxacin if the patient has chronic bronchopulmonary disease or prior fluoroquinolone exposure, as resistance rates are 11-30% for primary resistance and 19-30% for secondary resistance 1, 2, 4

The American College of Gastroenterology recommends that after failure of second-line therapy, treatment must be guided by antimicrobial susceptibility testing whenever possible 1, 2, 3
Obtain gastric biopsies from both antrum and fundus for culture and susceptibility testing to clarithromycin, levofloxacin, and other antibiotics 5
Molecular methods using PCR can detect point mutations responsible for clarithromycin and levofloxacin resistance more rapidly than traditional culture 5

Never reuse clarithromycin after quadruple therapy failure, as the patient likely has clarithromycin-resistant H. pylori (resistance occurs in two-thirds of standard triple therapy failures) 5
Do not repeat antibiotics to which the patient has been previously exposed, especially clarithromycin and levofloxacin, where resistance develops rapidly 4

Always use high-dose PPI twice daily (not once daily), taken 30 minutes before meals, as standard once-daily dosing is inadequate 4
Extend treatment duration to 14 days rather than 7-10 days, which improves eradication by approximately 5% 1, 2, 4

Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation 1, 2
Never use serology to confirm eradication, as antibodies persist long after successful treatment 1, 4